Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone
Phase 3
- Conditions
- Small Cell Lung Carcinoma
- Registration Number
- jRCT2080222136
- Lead Sponsor
- Bristol-Myers Squibb K.K.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 1100
Inclusion Criteria
Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) Eastern Cooperative Oncology Group (ECOG) of 0 or 1
Exclusion Criteria
Prior systemic therapy for lung cancer Symptomatic Central Nervous System (CNS) metastases History of autoimmune disease
Study & Design
- Study Type
- Interventional
- Study Design
- Randomized, Double Blind, Placebo Control, Parallel Assignment Study
- Primary Outcome Measures
Name Time Method - Overall Survival (OS) of subjects who received blinded study therapy
- Secondary Outcome Measures
Name Time Method